Sema4D Deficiency Enhances Glucose Tolerance Through Acceleration of GLUT2 Synthesis in Hepatocytes
Author:
Zhang Yanling1ORCID, Jiang Xiaomei2, Wu Dongsong2, Huang Hao2, Jia Guiqing2, Zhao Gaoping2ORCID
Affiliation:
1. Sichuan Academy of Medical Sciences and Sichuan People's Hospital 2. Sichuan Provincial People's Hospital: Sichuan Academy of Medical Sciences and Sichuan People's Hospital
Abstract
Abstract
The glucose transporter 2 (GLUT2) is constitutively expressed in pancreatic beta cells and hepatocytes in mice. It is the most important receptor in glucose-stimulated insulin release and hepatic glucose transport. The Sema4D is a signaling receptor on cell membranes. The correlation between Sema4D and GLUT2 has not been reported previously. We investigated whether knockdown of Sema4D could exert a hypoglycemic effect based on the increased GLUT2 expression in Sema4D -/- mice hepatocytes. First, Sema4D -/- male mice exhibited significantly greater glucose tolerance than wild-type mice in a hyperglycemic environment. Secondly, Sema4D -/- mice had more retained GLUT2 in liver membranes after streptozotocin (STZ) injection according to an immunofluorescence assay. After STZ injection, Sema4D -/- male mice did not exhibit fasting hyperinsulinemia like wild-type mice. Finally, analysis of metabolomic and immunohistochemical data also revealed that Sema4D -/- mice produce hypoglycemic effects by enhancing the pentose phosphate pathway, but not glycogen synthesis. Thus, Sema4D may play an important role in the regulation of glucose homeostasis by affecting GLUT2 synthesis.
Publisher
Springer Science and Business Media LLC
Reference58 articles.
1. HRD1, an Important Player in Pancreatic β-Cell Failure and Therapeutic Target for Type 2 Diabetic mouse;Wu T;Diabetes,2020 2. Tomic D, Shaw JE, Magliano DJ. (2022). The burden and risks of emerging complications of diabetes mellitus. Nature reviews. Endocrinology, 1–15. Advance online publication. https://doi.org/10.1038/s41574-022-00690-7. 3. Li, S., Vandvik, P. O., Lytvyn, L., Guyatt, G. H., Palmer, S. C., Rodriguez-Gutierrez,R., Foroutan, F., Agoritsas, T., Siemieniuk, R., Walsh, M., Frere, L., Tunnicliffe,D. J., Nagler, E. V., Manja, V., Åsvold, B. O., Jha, V., Vermandere, M., Gariani,K., Zhao, Q., Ren, Y., … Mustafa, R. A. (2021). SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ (Clinical research ed.), 373, n1091. https://doi.org/10.1136/bmj.n1091. 4. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus;Magkos F;Nat Rev Endocrinol,2020 5. GLUT2, glucose sensing and glucose homeostasis;Thorens B;Diabetologia,2015
|
|